The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

This test complements Fujirebio’s growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company’s leading position in advancing neuro biomarker research ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic ...

Developed by Fujirebio Diagnostics, the test measures the ratio between tau and amyloid proteins in the blood and ties its findings to the likelihood of finding plaque buildups in the brain.

A blood test that can be administered in the first trimester of pregnancy identified women at risk for developing preeclampsia 5 months before symptom onset, data show. Researchers said the test — a ...

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of ...

A groundbreaking study of nearly 45,000 people shows how a blood test measuring proteins can estimate which organs are aging ...

While most people mark their age by the number of birthdays they've celebrated, scientists have long known that the body's organs do not all age at ...